Endocrine Abstracts

Aim: Evaluate the data of anamnesis, clinical-laboratory parameters, magnetic resonance imaging (MRI) findings, response to treatment in children with hyperprolactinemia (HProlact).

Methods: We analyzed retrospectively 16 patients in the endocrinological department of University hospital (Minsk) with HProlact over 2004–2012 years. Boys (B) 6 (37.5%) (stage on Tanner 1 – 1 (17%); stage 2–3 – 3 (50%), stage 4 – 2 (33%), age at diagnosis 11.4–15.9 years; girls (G) 10 (62.5%) (stage on Tanner 1–3 (30%), stage 2–3 – 2 (20%), stage 4 – 5 (50%), age at diagnosis 0.8–16.4 years. We examined BMI; the levels of prolactin, thyroid-stimulating hormone (TSH), free thyroxine; MRI. The results were processed using the Statistica 6.1.

Results: In anamnesis B: breast increasing 4 (66%), delayed puberty 1 (17%); G: precocious thelarche 3 (30%), dismenorrhoea 2 (20%), galactorrhoea 1 (10%), delayed puberty 1 (10%), headache 1 (10%).

Prolactin B 49.8±3.9, G 48.9±4.2 (3–27.7 ng/ml) (P=0.6). Subclinical hypothyroidism was in 2 (33%) B and 4 (40%) G with TSH levels 6.4±1.8 and 5.7±1.1 (0.23–3.4 μIU/l) (P=0.2). The remaining B and G were euthyroid.

MRI confirmed the presence of microadenoma in 4 (66%) B and 5 (50%) G.

4 (66%) B and 4 (57.2%) G received treatment with bromocriptine (1.25–2.5 mg/day). 3 (42.8%) G were treated with cabergoline (500 μg/week). Normal prolactin levels were noted in all B after 8.7±3 month of treatment. G which received bromocriptine normal prolactin were after 3±1.7 month, cabergoline – 4±2 (P=0.1). Tumor decreasing from 5 till 3 mm by MRI were in all B and G after 9.6±2.5 months and 4.7±2.5 respectively.

Conclusions: HProlact syndrome is rare in children. All cured patients with HProlact demonstrated a good response to medical treatment by normalization of prolactin values and decreasing of tumor.